Tyrosine Pharma, Inc.
Every 40 seconds someone in the US suffers from stroke. Tyrosine Pharma is in development of a therapeutic treatment to reduce brain damage.
- Stage Product In Development
- Industry Biotechnology
- Location Albuquerque, NM, USA
- Currency USD
- Founded January 2013
- Employees 2
- Website tyrosinepharma.com
Company Summary
Dr. Surojit Paul, the product's inventor, has developed a method and formula to generate a cell-permeable STEP peptide that can bind constitutively to its substrates and is resistant to degradation. Preliminary studies have indicated that intravenous injection of the cell-permeable STEP peptide either before or after an acute ischemic stroke can provide significant protection against ischemic brain injury.
Team
-
Wayne LaslieCEO
Former Chief Operating Officer of Myriad Genetics & Myrexis. Over 30 years experience in Pharmaceutical commercialization
-
Alan KolodCFO
Former CFO of the Future Medical Systems Group (Switzerland). 30+ years in financial management and growing companies and leading them to positive exits.
-
Dr. Surojit PaulTechnologist
PhD in Neurosciences. Tenured Professor at University of New Mexico Health Sciences Center
-
Adrian HobdenBoard Member
Adrian is a successful pharmaceutical executive with a storied career that started with Glaxo Smith Kline and also included his role as the President of the Pharmaceutical Division of publicly-traded Myriad Genetics and CEO of publicly-traded Myrexis, Inc. a drug development company focused on cancer therapeutics. Adrian is a graduate of Cambridge University in the United Kingdom (UK) and holds a PhD degree in molecular biology from the Universi
Advisors
-
Peacock & Meyers (IP), Candice Lee Owens (Corporate)LawyerUnconfirmedThad Porch (Porch CPAs)AccountantUnconfirmed
Previous Investors
-
New Mexico AngelsUnconfirmedIPHC, LLCUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.